AURA BIOPHARM WINNER OF THE NORDIC STAR AWARD 2016 IN STOCKHOLM

AURA BIOPHARM WINNER OF THE NORDIC STAR AWARD 2016 IN STOCKHOLM

aura-award-3

AURA Biopharm, Eurocine Vaccines and Ocuspecto have been announced as the winners of Nordic Stars 2016 Awards (http://www.aurabiopharm.com/aura-biopharm-winner-of-the-nordic-star-award-2016-in-stockhol/). The awards were presented at the conclusion of the Nordic Life Science Days (NLSDays) in Stockholm, which again set a new record for attendance. More than 1 070 delegates representing over 680 companies from 36 countries joined the conference, thus accentuating NLSDays’ role as the premier Nordic life sciences event.

Nordic Stars Awards were introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.

– At SwedenBIO we are proud to present three winners of the Nordic Stars Awards 2016, each being passionate about developing solutions for their respective patient groups. Innovations like these, developed with impressive entrepreneurial spirit all contribute to sustainable healthcare, the theme of this year’s conference program, says Jonas Ekstrand, Director General at SwedenBIO.

This year’s winners are:

AURA Biopharm, Norway
Recently founded AURA Biopharm is developing a treatment for a serious rare autoimmune disease, Antiphospholipid Syndrome. Based in Oslo, but operating virtually and led by an International team of very experienced scientists, managers and experts, AURA Biopharm has developed an exciting collaborative business model with great possibilities to deliver future breakthrough therapies to the market.
www.aurabiopharm.com

Eurocine Vaccines, Sweden
Eurocine Vaccines will soon enter clinical trials with their nasal quadrivalent influenza vaccine particularly aimed for children under the age of 2 years. Based on their proprietary adjuvant technology, the company is targeting a patient population where current vaccines have low preventive effects and recommendations from authorities world-wide are likely to result in a growing market. A vaccine without a needle could no doubt be labelled ”patient centric”.
www.eurocine-vaccines.com

Ocuspecto, Finland
Ocuspecto has developed and commercialized a novel portable medical device for the examination of the neuro-visual system from the eye to the visual processing in the brain. This ”easy-to-use-almost-anywhere” cloud-based device will provide healthcare professionals with essential information to diagnose, prevent and with increased precision follow up treatments of vision defects, cataract, glaucoma and macular degeneration. Their slogan is ”your vision is our mission” – what else can you expect from a Nordic Star!
www.ocusweep.com